The restructuring of the Swiss pharmaceutical giant Novartis will cost a good seven percent of the workforce the job. In the course of the realignment of the main business with the patented drugs, around 8,000 jobs will be lost, as the company explained on Tuesday on request. “This restructuring could affect 1,400 jobs in Switzerland out of a total of around 8,000 jobs affected worldwide.” The drug manufacturer from Basel employs 108,000 people worldwide, and around 11,600 in Switzerland. In April, Novartis announced that it would position the dominant business with the patented drugs – called Innovative Medicines – geographically instead of according to therapeutic areas and focus more on the important US market to align This and other changes are expected to reduce overall selling expenses by at least $1 billion by 2024.
Pharmaceutical industry – Novartis cuts jobs – economy
